Clinical trials of ivosidenib and enasidenib, respectively mIDH1 and mIDH2 inhibitors, in newly diagnosed and R/R AML patients with IDH1/IDH2 mutations have improved chemotherapy response, and mutation-cleared AML patients had a longer duration of remission and a longer overall survival than patients without mutation clearance (3, 144–146). This evidence concerns the gene IDH1 and acute myeloid leukemia.